Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.68 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.60 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8654489 | 1.00 | TYR (0.68) | TYRSLC5A1SLC5A2POLB | |
| SCHEMBL8471395 | 1.00 | TYR (0.68) | TYRSLC5A1SLC5A2POLB | |
| SCHEMBL5404205 | 0.91 | TYR (0.63) | TYR | |
| SCHEMBL9352922 | 0.90 | TYR (0.61) | TYR | |
| SCHEMBL9352925 | 0.90 | TYR (0.61) | TYR | |
| SCHEMBL5032748 | 0.89 | TYR (0.71) | TYRSLC5A1SLC5A2POLB | |
| SCHEMBL14120404 | 0.89 | TYR (0.71) | TYRSLC5A1SLC5A2POLB | |
| SCHEMBL14705652 | 0.89 | TYR (0.71) | TYRSLC5A1SLC5A2POLB | |
| SCHEMBL467529 | 0.89 | TYR (0.71) | TYRSLC5A1SLC5A2POLB | |
| SCHEMBL5032151 | 0.89 | TYR (0.71) | TYRSLC5A1SLC5A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937167-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937167-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937167-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2015-01-20 | — | — | US | disclosed |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | TYR 270/4885SLC5A1 820/4885SLC5A2 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.